Michael Grundman
Impact in
- Psychiatry and Mental health top 0.1%
- Dementia and Cognitive Impairment Research
- Biological Psychiatry top 0.5%
Papers in
- Physiology 54
- Alzheimer's disease research and treatments 52
-
- Dementia and Cognitive Impairment Research 45
- Co-authors
- Mary Sano (15 shared papers)Leon J. Thal (20 shared papers)Ronald G. Thomas (22 shared papers)Steven H. Ferris (10 shared papers)Eric Pfeiffer (5 shared papers)Kimberly Schafer (9 shared papers)Shelia Jin (7 shared papers)Rachelle S. Doody (7 shared papers)
- Journals
- Alzheimer s & Dementia (28 papers)Alzheimer Disease & Associated Disorders (10 papers)Neurology (9 papers)Alzheimer s & Dementia Translational Research & Clinical Interventions (3 papers)Alzheimer s Research & Therapy (3 papers)
- Partner nations
- United StatesUnited KingdomCanada
In The Last Decade
Michael Grundman
112 papers receiving 14.2k citations
Michael Grundman's Hit Papers
Peers
Comparison fields: 5 of 152
- Psychiatry and Mental health 5.9k
- Biological Psychiatry 727
- Neurology 2.4k
- Physiology 7.0k
- Geriatrics and Gerontology 726
Countries citing papers authored by Michael Grundman
This map shows the geographic impact of Michael Grundman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Grundman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Grundman more than expected).
Fields of papers citing papers by Michael Grundman
This network shows the impact of papers produced by Michael Grundman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Grundman. The network helps show where Michael Grundman may publish in the future.
Co-authors
The 25 scholars most cited alongside Michael Grundman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 115 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease Hit paper breakdown → | 1997 | 1789 |
| 2 | Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment Hit paper breakdown → | 2005 | 1330 |
| 3 | An Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimerʼs Disease Hit paper breakdown → | 1997 | 953 |
| 4 | Mild Cognitive Impairment Can Be Distinguished From Alzheimer Disease and Normal Aging for Clinical Trials Hit paper breakdown → | 2004 | 764 |
| 5 | Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. Hit paper breakdown → | 2003 | 744 |
| 6 | Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. Hit paper breakdown → | 2000 | 736 |
| 7 | Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup Hit paper breakdown → | 2011 | 554 |
| 8 | 11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study Hit paper breakdown → | 2010 | 536 |
| 9 | Validity and Reliability of the Alzheimerʼs Disease Cooperative Study-Clinical Global Impression of Change Hit paper breakdown → | 1997 | 528 |
| 10 | 1997 | 495 | |
| 11 | Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. | 1997 | 400 |
| 12 | 2012 | 366 | |
| 13 | 2000 | 340 | |
| 14 | 2003 | 281 | |
| 15 | 2000 | 229 | |
| 16 | 2018 | 224 | |
| 17 | The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease Hit paper breakdown → | 2020 | 208 |
| 18 | 2000 | 207 | |
| 19 | 2009 | 191 | |
| 20 | 2016 | 185 |
About Michael Grundman
Michael Grundman is a scholar working on Physiology, Psychiatry and Mental health, Molecular Biology, Pharmacology and Neurology, having authored 115 papers that have together received 14.8k indexed citations. Recurring topics across this work include Alzheimer's disease research and treatments (52 papers), Dementia and Cognitive Impairment Research (45 papers), Cholinesterase and Neurodegenerative Diseases (18 papers), Health Systems, Economic Evaluations, Quality of Life (13 papers), Computational Drug Discovery Methods (9 papers), Parkinson's Disease Mechanisms and Treatments (9 papers), Neuroinflammation and Neurodegeneration Mechanisms (7 papers) and Functional Brain Connectivity Studies (7 papers). The work is most often cited by research in Psychiatry and Mental health (5.9k citations), Biological Psychiatry (727 citations), Neurology (2.4k citations), Physiology (7.0k citations) and Geriatrics and Gerontology (726 citations). Michael Grundman has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Mary Sano, Leon J. Thal, Ronald G. Thomas, Steven H. Ferris, Eric Pfeiffer, Kimberly Schafer, Shelia Jin, Rachelle S. Doody, Carl W. Cotman and Christopher Ernesto. Their work appears in journals such as Alzheimer s & Dementia, Alzheimer Disease & Associated Disorders, Neurology, Alzheimer s & Dementia Translational Research & Clinical Interventions and Alzheimer s Research & Therapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.